Analysts expect Aimmune Therapeutics Inc (NASDAQ:AIMT) to post earnings of ($0.70) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aimmune Therapeutics’ earnings, with estimates ranging from ($0.84) to ($0.62). Aimmune Therapeutics posted earnings of ($0.55) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 27.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($2.53) per share for the current financial year, with EPS estimates ranging from ($2.63) to ($2.45). For the next financial year, analysts anticipate that the company will post earnings of ($2.82) per share, with EPS estimates ranging from ($3.31) to ($2.27). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Aimmune Therapeutics.
A number of research firms have weighed in on AIMT. BidaskClub raised Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, January 11th. Wedbush reaffirmed an “outperform” rating and set a $70.00 target price on shares of Aimmune Therapeutics in a report on Friday, December 1st. ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $57.22.
Aimmune Therapeutics (NASDAQ:AIMT) traded up $0.71 during mid-day trading on Wednesday, reaching $33.96. The company’s stock had a trading volume of 517,110 shares, compared to its average volume of 1,016,580. The stock has a market cap of $1,720.00 and a price-to-earnings ratio of -16.36. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $42.00.
In other Aimmune Therapeutics news, CFO Eric Bjerkholt acquired 3,125 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was bought at an average price of $32.00 per share, with a total value of $100,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Douglas T. Sheehy sold 1,875 shares of the business’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $39.44, for a total value of $73,950.00. Following the transaction, the insider now directly owns 1,875 shares of the company’s stock, valued at approximately $73,950. The disclosure for this sale can be found here. In the last three months, insiders have bought 58,093 shares of company stock valued at $1,858,976 and have sold 133,968 shares valued at $5,073,180. 17.59% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new position in shares of Aimmune Therapeutics during the fourth quarter worth about $646,000. Glenmede Trust Co. NA purchased a new position in shares of Aimmune Therapeutics during the fourth quarter worth about $661,000. Raymond James & Associates grew its holdings in shares of Aimmune Therapeutics by 7.2% during the fourth quarter. Raymond James & Associates now owns 24,737 shares of the biotechnology company’s stock worth $936,000 after purchasing an additional 1,669 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Aimmune Therapeutics during the fourth quarter worth about $18,702,000. Finally, Highland Capital Management LP purchased a new position in shares of Aimmune Therapeutics during the fourth quarter worth about $5,663,000. 62.04% of the stock is owned by institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.